Genetic Testing Doesn't Cause Undue Worry for Breast Cancer Patients

Newer genetic tests introduce more ambiguity, but a new study finds patients are not overreacting to uncertain results.

11:00 AM

Author | Nicole Fawcett

Genetic testing for breast cancer has become more complex. Newer tests now evaluate a panel of multiple genes, compared to older tests looking only at BRCA genes.

The new complexity often brings more uncertainty about the results. But, a new study finds that these more extensive tests are not causing patients to worry more about their cancer risk.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes, Google Play and Stitcher.

"Genetic testing is becoming increasingly more complex, but increasingly more precise. This has led to some ambiguity in test results. The challenge is incorporating this information into the treatment decision without causing unnecessary worry," says lead study author Steven J. Katz, M.D., MPH, professor of general medicine and of health management and policy at the University of Michigan.

A variant of unknown significance

Initially, genetic testing for breast cancer focused exclusively on BRCA1 and BRCA2 genes. Now, newer multigene panel tests look for abnormalities in a dozen or more different genes that play some role in breast cancer risk. By testing more genes, it's more likely a patient will have a positive test or a variant of unknown significance — in other words, something is out of the ordinary but doctors will not know how that impacts cancer risk.

SEE ALSO: Decision Support Tool Boosts Genetic Testing Knowledge in Breast Cancer Patients

The concern is that this greater variation could lead patients to worry too much about their risk of breast cancer recurring when the genetic testing results are ambiguous.

Researchers surveyed 1,063 women treated for early stage breast cancer who had received genetic testing between 2013-2015, the period in which panel testing became more popular. About 60 percent of the patients were tested only for BRCA1 and BRCA2, while 40 percent had the multigene panel test. Patients were asked how much and how often they worried about their cancer coming back and the impact that worry had on their life.

Overall, 11 percent of patients reported that cancer worry had a high impact on their life and 15 percent worried often or almost always. Neither the impact nor the frequency of worry varied substantially based on the type of genetic testing or the test results. The study is published in JCO Precision Oncology.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

"These findings are reassuring," Katz says. "We found that patients did not overreact whether they got the newer panel testing or BRCA-only testing, and they did not overreact to the test results. Their future cancer worry was not different whether they had a negative test or variant of unknown significance."

Genetic counseling

Virtually all of the patients surveyed received some form of genetic counseling. 

"Genetic counseling is essential to maximize the benefit of testing for patients and their families," says senior study author Allison W. Kurian, M.D., M.Sc., associate professor of medicine and of health research and policy at Stanford University. "But timely counseling after diagnosis of breast cancer is increasingly a challenge because more patients are getting tested and the results are more complex."


More Articles About: Lab Report Breast cancer Genetic Testing Cancer and Genetics Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories white pills falling out of orange pill bottle on a brown surface
Health Lab
Drug combination reduces breast cancer risk and improves metabolic health in rats
Researchers investigated the combined effects of bazedoxifene and conjugated estrogens in rat models as an alternative to tamoxifen.
woman with brown hair smiling and painting on right
Health Lab
Finding a 'beautiful gift' within stage 4 lung cancer
How one woman found 'a beautiful gift' within stage 4 lung cancer.
Smiling photo of Jill Martin. She is standing in a white space wearing a dark plush coat, jeans, and sneakers.
Philanthropy News
TODAY show star and breast cancer survivor helps raise support for women’s health
TODAY show star Jill Martin aims to help improve health care for all women through the Women's Health Luncheon.
Smiling professional headshot of Mary Vandewiele.
Philanthropy News
Entrepreneur bridges gaps in integrative oncology
Mary Vandewiele's commitment to integrative oncology training programs is a powerful example of how philanthropy advances patient care.
circular image colorful on navy background
Health Lab
23andMe is potentially selling more than just genetic data
An expert shares details about the privacy issues and genetic data with 23andMe happening.
breast cancer checking graphic image in different pinks
Health Lab
How to assess your risk for breast cancer
Melissa Pilewskie, M.D., answers questions about how you can accurately assess your risk and what lifestyle changes can help reduce the likelihood of developing breast cancer.